AzTrials
AzTrials

Developmental and Epileptic EncephalopathyPhase 3NCT06908226

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

A Phase 3 study testing LP352 in people with Developmental and Epileptic Encephalopathy, run by Longboard Pharmaceuticals at 88 sites in 17 countries.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. Read more about this study

Who is it for?
Ages 2 to 66 years
What is being tested?
LP352
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
324 participants
Where
88 sitesin 17 countries
Study dates
12 Feb 2025to 17 Dec 2027
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 66 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • The participant has satisfactorily completed Study LP352-301 or LP352-302 Visit 8, and who, in the opinion of the investigator, may benefit from continued LP352 administration.
  • Diagnosis of DEE that includes Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS), or DEE Other (as defined and evaluated in Study LP352-301 or LP352-302).
  • Participant has a body weight of ≥10 kg.
  • G-tubes/PEG tubes (if applicable) should be in stable and good working condition. Nasogastric tubes are not allowed except for short-term management.
  • Has at least one reliable and consistent parent, legal guardian, or caregiver during the study.
  • The participant must be willing and able to provide written informed consent; in instances where the participant is unable to provide consent, an appropriate LAR must provide informed consent and the participant will need to assent (as per local regulations) before participation in the study. If the participant cannot provide consent or assent (ie, due to developmental status), the investigator should document why it was not obtained.
Show all 10Show fewer
  • The participant and/or authorized representative is willing to provide written consent or assent to allow the investigator and the investigator's staff to consult with the participant's medical caregivers and the medical monitor during Screening and during participation in the study.
  • All participants of childbearing potential must have a negative urine or serum pregnancy (human chorionic gonadotropin) test at Visit 8 from Study LP352-301 or LP352-302 and agrees to routinely use an acceptable effective method of contraception from the time of signing informed consent up to 48 hours after the last dose of study drug.
  • Participant and/or participant's caregiver(s) agree to not post any participant's personal medical data related to the study or information related to the study on any website or social media site until the study has been completed.
  • The participant, parent, or caregiver is willing and able (in the judgment of the investigator) to comply with completion of the diaries throughout the study.

Who cannot join

  • The participant is receiving exclusionary medications.
  • Considered at risk of suicidal behavior based on the C-SSRS at Visit 8 of LP352-301 or LP352-302. If the participant is unable to complete the C-SSRS due to developmental status, the participant's LAR may not complete the C-SSRS. In these cases, the investigator may use clinical judgment to assess both the participant's status regarding suicidality and the ability to complete the scale, both of which must then be documented in the source document.
  • Has a PHQ-9 score of >9 or a positive response to Question 9 at Visit 8 of LP352-301 or LP352-302. If the participant is unable to complete the PHQ-9, the participant's LAR may not complete the PHQ-9. In these cases, the investigator may use clinical judgment to assess both the participant's status and ability to complete the scale, both of which must then be documented in the source document.
  • Ongoing AE from LP352-301 or LP352-302 of severe depression, anorexia nervosa, or bulimia per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
  • Has an abnormal and clinically significant 12-lead ECG at Visit 8 in LP352-301 or LP352-302 in the opinion of the investigator, for example, second- or third-degree heart block or a QTc of >450 msec for adult males, >470 msec for adult females, or >440 msec for pediatric participants.
  • Ongoing AE in LP352-301 or LP352-302 of alcohol, opioid, or other drug use disorder, as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
Show all 13Show fewer
  • Current use of any cannabis product or cannabidiol that is not in oral solution/capsule/tablet form, not obtained from a government-approved dispensary, or containing ≥50% THC. Cannabis product or cannabidiol should be used primarily to treat seizures and dose should not be adjusted for the duration of the study. Cannabis product or cannabidiol will count as a concurrent ASM.
  • Has a positive result on the urine drug screen at Visit 8 of LP352-301 or LP352-302, except for positive results related to prescribed controlled medications (eg, benzodiazepine) or Epidiolex®/government-approved cannabis product/cannabidiol used to treat seizures (eg, tetrahydrocannabinol).
  • Unstable, clinically significant neurologic (other than the disease being studied, eg, recurrent strokes), psychiatric, cardiovascular (eg, pulmonary arterial hypertension, cardiac valvulopathy, orthostatic hypotension/tachycardia) pulmonary, hepatic (severe hepatic impairment), renal (severe renal impairment), metabolic, gastrointestinal, urologic, immunologic, hematopoietic, or endocrine disease or other abnormality at Visit 8 of LP352-301 or LP352-302 which may impact the ability of the participant to participate or potentially confound the study results.
  • Is pregnant, breast-feeding, or intending to become pregnant during or within 48 hours after the last dose of study drug; or intending to donate ova during such time period.
  • Has a known hypersensitivity to any component of LP352 formulation or any history of serious drug-induced hypersensitivity, eg, toxic epidermal necrolysis or Drug Reaction with Eosinophilia and Systemic Symptoms.
  • Unwilling to abstain from donation of blood during and within 2 weeks after the study.
  • Is unable or unwilling to comply with any of the study requirements or timelines.

Trial locations and contacts

88 sites in 17 countries. Contact the study team or a site near you to ask about taking part.

88 sites in 17 countries

United States21 sites

  • Children's Hospital Colorado - Heart Institute

    Aurora, Colorado, 80045-7106

  • Child Neurology Consultants of Austin - Austin

    Austin, Texas, 78731-3157

  • Mid-Atlantic Epilepsy and Sleep Center - Bethesda

    Bethesda, Maryland, 20817-1844

  • Consultants in Epilepsy & Neurology, PLLC

    Boise, Idaho, 83702-5029

  • Massachusetts General Hospital (MGH)

    Boston, Massachusetts, 02114

  • NW FL Clinical Research Group, LLC

    Gulf Breeze, Florida, 32561-4495

  • The University of Texas Medical School at Houston - UT Gastroenterology

    Houston, Texas, 77030-1517

  • University of Iowa Health Care Medical Center (University of Iowa Hospitals & Clinics)

    Iowa City, Iowa, 52242-1009

  • Arkansas Children's Hospital - Cardiology Clinic

    Little Rock, Arkansas, 72202-3500

  • Barnabas Health - Institute of Neurology and Neurosurgery

    Livingston, New Jersey, 07039-5817

  • University of California Los Angeles (UCLA) - David Geffen School of Medicine - Global Health Pro...

    Los Angeles, California, 90095

  • University of Miami Medical Group (UMMG)

    Miami, Florida, 33136-2117

  • Northeast Regional Epilepsy Group - Morristown

    Morristown, New Jersey, 07960-6092

  • NYU Langone Health-NYU Comprehensive Epilepsy Center

    New York, New York, 10016-4852

  • Research Institute of Orlando LLC

    Orlando, Florida, 32806

  • Stanford University - Stanford School of Medicine - Pulmonary and Cystic Fibrosis Center

    Palo Alto, California, 94304-1511

  • Oregon Health & Science University - Blood Brain Barrier and Neuro-Oncology Program

    Portland, Oregon, 97239-3098

  • Mayo Clinic - Children's Center - Rochester

    Rochester, Minnesota, 55905-0001

  • UCSF Benioff Children's Hospitals - San Francisco

    San Francisco, California, 94158

  • Pediatric Epilepsy & Neurology Specialists (PENS)

    Tampa, Florida, 33609-4191

  • University of South Florida (USF) - Tampa Campus

    Tampa, Florida, 33620

Other trials in United States

Spain9 sites

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035

  • Hospital de la Santa Creu I Sant Pau

    Barcelona, 8041

  • Hospital Sant Joan de Deu Barcelona (HSJDB)

    Esplugues de Llobregat, Barcelona, 08950

  • Hospital Infantil Universitario Nino Jesus (HIUNJS)

    Madrid, 28009

  • Hospital Universitario Vithas Madrid La Milagrosa

    Madrid, 28010

  • Hospital Ruber Internacional

    Madrid, 28034

  • Hospital Regional Universitario de Malaga - Hospital General

    Málaga, 29010

  • Hospital Universitario de Navarra

    Pamplona, Navarre, 31008

  • Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur)

    Valencia, 46026

Other trials in Spain

Japan8 sites

  • National Center of Neurology and Psychiatry-National Center Hospital

    Kodaira-shi, Tokyo-To, 187-8551

  • Dokkyo Medical University Hospital

    Mibu-Machi, Tochigi, 321-0293

  • International University of Health and Welfare - Narita Hospital

    Narita-shi, Chiba, 286-8520

  • National Hospital Organization Nishi-Niigata Chuo National Hospital

    Niigata, 950-2074

  • Okayama University Hospital

    Okayama, Okayama-ken, 700-8558

  • Osaka City General Hospital

    Osaka, Osaka, 534-0021

  • Saitama Prefectural Children's Medical Center

    Saitama-shi, Saitama, 330-8777

  • National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders

    Shizuoka, 420-0953

Other trials in Japan

France7 sites

  • Hospices Civils de Lyon (HCL) - Hopital Pierre Wertheimer

    Bron, Auvergne-Rhône-Alpes, 69500

  • Hôpital Roger Salengro

    Lille, Nord, 59000

  • AP-HM- Hôpital de La Timone

    Marseille, 13005

  • AP-HP - Hôpital universitaire Necker-Enfants malades

    Paris, 75015

  • AP-HP - Hôpital universitaire Robert-Debré

    Paris, 75019

  • Les Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre

    Strasbourg, Ain, 67098

  • CHU de Toulouse - Hôpital Pierre-Paul Riquet

    Toulouse, 31059

Other trials in France

Italy7 sites

  • Azienda Ospedaliero-Universitaria - Ospedale Pediatrico Meyer

    Florence, Florence, 50139

  • Istituto Giannina Gaslini (Ospedale Pediatrico IRCCS) - Centro Malattie Rare

    Genoa, 16147

  • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

    Milan, 20133

  • Fondazione Mondino, IRCCS Istituto Neurologico Nazionale a Carattere Scientifico

    Pavia, 27100

  • Ospedale Pediatrico Bambino Gesu - Gianicolo

    Rome, 00165

  • Universita Cattolica del Sacro Cuore - Fondazione Policlinico Universitario A Gemelli - Centro pe...

    Rome, 00168

  • Azienda Ospedaliera Universitaria Integrata Verona - Centro Fibrosi Cistica di Verona (CFC Verona)

    Verona, 37126

Other trials in Italy

Australia6 sites

  • Royal Brisbane and Women's Hospital (RBWH)

    Brisbane, Queensland, 4006

  • Queensland Children's Hospital (Lady Cilento Children's Hospital)

    Brisbane, Queensland, 4101

  • Austin Hospital

    Heidelberg, Victoria, 3084

  • The Royal Children's Hospital (RCH) Melbourne

    Parkville, Victoria, 3052

  • Sydney Children's Hospital - Randwick

    Randwick, New South Wales, 2031

  • The Children's Hospital-Westmead - Heart Centre for Children

    Westmead, New South Wales, 2145

Other trials in Australia

China6 sites

  • Peking University First Hospital (Beida Hospital)

    Beijing, Beijing Municipality, 100034

  • Capital Medical University-Beijing Children's Hospital

    Beijing, Beijing Municipality, 100045

  • Guangzhou Medical University-The Second Affiliated Hospital

    Guangzhou, Guangdong, 510260

  • Fudan University - Children's Hospital

    Shanghai Shi, Shanghai Municipality, 201102

  • Shenzhen Children's Hospital

    Shenzhen Shi, Guangdong, 518026

  • Wuhan Children's Hospital

    Wuhan, Hubei, 430016

Other trials in China

United Kingdom5 sites

  • Cardiff and Vale University Health Board - University Hospital of Wales (UHW) - Noah's Ark Childr...

    Cardiff, East Wales, CF14 4XW

  • NHS Greater Glasgow and Clyde-Glasgow Clinical Research Facility - Queen Elizabeth University Hos...

    Glasgow, South Western Scotland, G51 4TF

  • University College London Hospitals NHS Foundation Trust (UCLH)

    London, NW1 2PG

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, WC1N 3JH

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust - Royal Victoria Infirmary (RVI)

    Newcastle upon Tyne, North East, NE1 4LP

Other trials in United Kingdom

Germany4 sites

  • Gesellschaft fuer Epilepsieforschung e.V.

    Bielefeld, North Rhine-Westphalia, 33617

  • Universitätsklinikum Bonn

    Bonn, North Rhine-Westphalia, 53127

  • Universitätsklinikum Frankfurt - Klinikum der Goethe-Universität

    Frankfurt am Main, 60596

  • Universitaetsklinikum Schleswig-Holstein (UKSH) - Campus Kiel - Klinik fuer Psychosomatik und Psy...

    Kiel, Schleswig-Holstein, 24105

Other trials in Germany

Brazil3 sites

  • Instituto de Neurologia de Curitiba (INC)

    Curitiba, Paraná, 81210-310

  • Moinhos de Vento Hospital (Hospital Moinhos de Vento) (HMV)

    Porto Alegre, Rio Grande do Sul, 90035-001

  • Universidade de Sao Paulo (USP) - Hospital das Clinicas da Faculdade de Medicina (HCFMUSP) - Inst...

    São Paulo, 05403-903

Other trials in Brazil

Portugal3 sites

  • Hospital Pediátrico de Coimbra

    Coimbra, 3000-602

  • Unidade Local de Saude Santa Maria, E.P.E (ULSSM)

    Lisbon, 1649-035

  • Centro Hospitalar Universitario de Santo Antonio - Centro Materno Infantil do Norte (CMIN)

    Porto, 4050

Other trials in Portugal

Serbia3 sites

  • Univerzitetski Klinicki Centar Srbije - Klinika za Neurologiju

    Belgrade, Beograd, 11000

  • Institut za Zdravstvenu Zastitu Majke i Deteta Srbije Dr Vukan Cupic

    Belgrade, Beograd, 11070

  • University of Belgrade-Faculty of Medicine - Clinic of Neurology and Psychiatry for Children and ...

    Belgrade, Beograd, 112112

Other trials in Serbia

Belgium2 sites

  • Universitair Ziekenhuis Antwerpen (UZA)

    Edegem, Antwerp, 2650

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven, Flemish Brabant, 3000

Other trials in Belgium

Canada1 site

  • The Hospital for Sick Children (SickKids)

    Toronto, Ontario, M5G 1X8

Other trials in Canada

Latvia1 site

  • Bernu Kliniska Universitates Slimnica (BKUS) (University Children's Hospital)

    Riga, LV-1004

Other trials in Latvia

Mexico1 site

  • Instituto Nacional de Pediatria (INP) (National Institute of Pediatrics)

    Mexico City, Mexico City, 04530

Other trials in Mexico

Netherlands1 site

  • Universitair Medisch Centrum Utrecht - Polikliniek Oogheelkunde

    Utrecht, 3584 CX

Other trials in Netherlands

About this study

Official title: A Phase 3, Open-Label Study to Investigate the Long-Term Safety and Efficacy of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathy

This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.

Being tested
LP352
Keywords
Developmental and Epileptic Encephalopathy, LP352, Bexicaserin, Seizures, DEEp OLE, Antiseizure medications, Epilepsy, Neurodevelopmental disorders, Dravet syndrome, Lennox-gastaut syndrome
Medical subject headings
Seizures, Epilepsy, Neurodevelopmental Disorders, Epilepsies, Myoclonic, Lennox Gastaut Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LP352Drug

    Also called Bexicaserin

    LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube.

Study groups in NCT06908226
Study groupRoleWhat they receive
LP352ExperimentalParticipants will be titrated up to highest tolerated dose of LP352 during the Titration period (Visit 1 - Visit 3), followed by maintenance period (Visit 4 - Visit 14) and then taper/down titration period (Visit 15 - Visit 17).
Receives: Drug: LP352

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants reporting Treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) and AEs leading to discontinuation

    An AE is defined as any untoward medical occurrence in a participant enrolled into this study, regardless of its causal relationship to the study drug. A treatment-emergent AE is defined as any event that is not present before exposure to study drug or any event or condition that is already present that worsens in either intensity or frequency after exposure to study drug. An SAE is defined as any event that: Results in death; Is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization. "Inpatient hospitalization" includes admission to an emergency room for observation and/or treatment that would have been insufficient in an outpatient setting; results in persistent or significant disability/incapacity; Is a congenital anomaly/birth defect or is an important medical event. An adverse event of special interest (AESI) is an AE or SAE is defined as an AE or SAE of scientific or medical concern specific to the sponsor's product or program.

    Measured: Up to 61 Weeks

  2. Number of Participants With Clinically Significant Changes in Chemistry parameters

    Measured: Up to 61 Weeks

  3. Number of Participants With Clinically Significant Changes in Hematology parameters

    Measured: Up to 61 Weeks

  4. Number of Participants With Clinically Significant Changes in Urinalysis

    Measured: Up to 61 Weeks

  5. Number of participants with clinically significant changes in vital signs

    Measured: Up to 61 Weeks

  6. Number of participants with clinically significant changes in physical examinations

    Measured: Up to 61 Weeks

  7. Number of participants with clinically significant changes in growth parameters

    Measured: Up to 61 Weeks

  8. Number of participants with clinically significant changes in electrocardiogram (ECG) parameters

    Measured: Up to 61 Weeks

  9. Number of participants with postive responses to Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS was developed by researchers at Columbia University as a tool to help systematically assess suicidal ideation and behavior. It is composed of questions addressing suicidal ideation and suicidal behavior, as well as self-injurious behavior without suicidal intent. The tool will be administered by a trained operator/interviewer (investigator or designee) via interview with the participant at the study time points. If the participant is unable to complete the C-SSRS due to developmental status, the participant's legally acceptable representative may not complete the C SSRS. In these cases, the investigator may use clinical judgment to assess both the participant's status regarding suicidality and ability to complete the scale, both of which must then be documented in the source document.

    Measured: Up to 61 Weeks

  10. Number of participants with positive responses to Patient Health Questionnaire-9 (PHQ-9) and Question 9

    The PHQ-9 is a multipurpose instrument for Screening, diagnosing, monitoring, and measuring the severity of depression. The scale is an easy-to-use participant questionnaire that is a self-administered version of the Primary Care Evaluation of Mental Disorders diagnostic instrument for common mental disorders. The PHQ-9 is the depression module, which scores each of the 9 Diagnostic and Statistical Manual of Mental Disorders IV, Text Revision criteria as "0" (not at all) to "3" (nearly every day). It has been validated for use in primary care. Participants with a depression score of greater than 9 (mild) on the PHQ-9 scale or a positive response to Question 9 should be excluded from the study. When there is a positive response to PHQ-9 Question 9 post randomization, the investigator should determine whether an AE has occurred.

    Measured: Up to 61 Weeks

Secondary outcomes (3)

  1. Frequency Percent Change in Countable Motor Seizures During Treatment Compared to Baseline

    The percent change from Baseline in countable motor seizure frequency during Treatment will be calculated as (countable motor seizure frequency during Treatment) - (countable motor seizure frequency during Baseline [Visit 1 of LP352-301 and LP352-302]) ÷ seizure frequency during Baseline [Visit 1 of LP352-301 and LP352-302]) × 100

    Measured: Baseline and up to 55 weeks

  2. Percentage of participants with ≥ 50% Reduction in countable motor seizures during Treatment compared to Baseline [Visit 1 of LP352-301 and LP352-302]

    Measured: Baseline and up to 55 weeks

  3. Frequency Percent Change in Countable Motor Seizures during Maintenance compared to Baseline [Visit 1 of LP352-301 and LP352-302]

    Measured: Baseline and up to 55 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Apr 2025
  2. Study start12 Feb 2025
  3. Primary completion11 Nov 2027 (estimated)
  4. Study completion17 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
324 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06908226
Sponsor's protocol ID
LP352-303
Other IDs
2024-514974-39-00
Status last verified
Oct 2026
First submitted
6 Mar 2025
Last updated
14 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing LP352 in people with Developmental and Epileptic Encephalopathy, run by Longboard Pharmaceuticals at 88 sites in 17 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 14 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 88 sites in United States, Spain, Japan, France, Italy and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of participants reporting Treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) and AEs leading to discontinuation (time frame: Up to 61 Weeks). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06908226.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in